These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30426671)

  • 41. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
    Barrington SF; Kluge R
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [
    Xiao L; Yang J; Zhu H; Zhou M; Li J; Liu D; Tang Y; Feng L; Hu S
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1651-1661. PubMed ID: 38182838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.
    Reyal Y; Kayani I; Bloor AJC; Fox CP; Chakraverty R; Sjursen AM; Fielding AK; Ben Taylor M; Bishton MJ; Morris EC; Thomson KJ; Russell N; Mackinnon S; Peggs KS
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1234-1241. PubMed ID: 27095691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
    Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E
    Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].
    Kluge R; Körholz D
    Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
    Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 51. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
    Kluge R; Wittig T; Georgi TW; Kurch L; Sabri O; Wallace WH; Klekawka T; Fernández-Teijeiro A; Ceppi F; Karlén J; Pears J; Cepelová M; Fosså A; Beishuizen A; Hjalgrim LL; Körholz D; Mauz-Körholz C; Hasenclever D
    J Nucl Med; 2021 Mar; 62(3):338-341. PubMed ID: 32764122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
    Lamonica D; Graf DA; Munteanu MC; Czuczman MS
    J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
    Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
    Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-FDG PET in malignant lymphoma: significance of positive findings.
    Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [FDG-PET in Hodgkin lymphoma].
    Kobe C; Dietlein M; Mauz-Körholz C; Engert A; Borchmann P; Sabri O; Schober O; Schicha H; Kluge R
    Nuklearmedizin; 2008; 47(6):235-8; quiz N75-6. PubMed ID: 19057796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Automated quantification of reference levels in liver and mediastinal blood pool for the Deauville therapy response classification using FDG-PET/CT in Hodgkin and non-Hodgkin lymphomas.
    Sadik M; Lind E; Polymeri E; Enqvist O; Ulén J; Trägårdh E
    Clin Physiol Funct Imaging; 2019 Jan; 39(1):78-84. PubMed ID: 30284376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.